Sapphire licenses RC-1291 to Ono

6 November 2006

Sapphire Therapeutics, a privately-held US biopharmaceutical company that develops compounds acting within the ghrelin pathway for metabolic and oncologic diseases, has licensed a novel drug candidate for treating cancer anorexia/cachexia to Japan's Ono Pharmaceutical. Ono has obtained exclusive rights to develop and commercialize RC-1291 in Japan, Korea and Taiwan in return for upfront fees and milestone payments, as well as royalties on sales. Further financial terms were not disclosed. Ono plans to start Phase I trials of the drug in Japan in the second quarter of 2007.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight